Structure-fluorescence relationship of push-pull 2-phenylbenzothiazole derivatives designed based on the firefly light-emitter

Tailoring the AIE Chromogen 2-(2-Hydroxyphenyl)benzothiazole for Use in Enzyme-Triggered Molecular Brachytherapy

A targeted strategy for treating cancer is antibody-directed enzyme prodrug therapy, where the enzyme attached to the antibody causes conversion of an inactive small-molecule prodrug into an active drug. A limitation may be the diffusion of the active drug away from the antibody target site. A related strategy with radiotherapeutics entails enzymatically promoted conversion of a soluble to insoluble radiotherapeutic agent, thereby immobilizing the latter at the target site. Such a molecular brachytherapy has been scarcely investigated. In distinct research, the advent of molecular designs for aggregation-induced emission (AIE) suggests translational use in molecular brachytherapy. Here, several 2-(2-hydroxyphenyl)benzothiazole substrates that readily aggregate in aqueous solution (and afford AIE) were elaborated in this regard. In particular, (1) the 2-(2-hydroxyphenyl) unit was derivatized to bear a pegylated phosphodiester that imparts water solubility yet undergoes enzymatic cleavage, and (2) a p-phenol unit was attached to the benzo moiety to provide a reactive site for final-step iodination (here examined with natural abundance iodide). The pegylated phosphodiester-iodinated benzothiazole undergoes conversion from aqueous-soluble to aqueous-insoluble upon treatment with a phosphatase or phosphodiesterase. The aggregation is essential to molecular brachytherapy, whereas the induced emission of AIE is not essential but provides a convenient basis for research development. Altogether, 21 compounds were synthesized (18 new, 3 known via new routes). Taken together, blending biomedical strategies of enzyme prodrug therapy with materials chemistry concerning substances that undergo AIE may comprise a step forward on the long road toward molecular brachytherapy.

Fungal Light Emitter: Understanding Its Chemical Nature and pH-Dependent Emission in Water Solution

Fungal bioluminescence is a fascinating natural process, standing out for the continuous conversion of chemical energy into light. The structure of fungal oxyluciferin (light emitter) was proposed in 2017, being different and more complex than other oxyluciferins. The complexity of fungal oxyluciferin arises from diverse equilibria such as keto/enol tautomerization or deprotonation equilibria of four titratable groups. For this reason, still some crucial details of its structure remain unexplored. To obtain further structural information, a combined experimental and computational study of natural and three synthetic fungal oxyluciferin analogues has been performed. Here, we state the most stable chemical form of fungal oxyluciferin regarding its keto and enol tautomers, in the ground and excited states. We propose the (3Z,5E)-6-(3,4-dihydroxyphenyl)-4-hydroxy-2-oxohexa-3,5-dienoic acid form as the light emitter (fluorescent state) in water solution. Moreover, we show that chemical modifications on fungal oxyluciferin can affect the relative stability of the conformers. Furthermore, we show the clear effect of pH on emission. General conclusions about the role of these titratable groups in emission modulation have been drawn, such as the key role of dihydroxyphenyl deprotonation. This study is key to further analyze the properties of fungal bioluminescence and propose novel synthetic analogues.